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1. Introduction 1 
This expert consensus statement of the European Heart Rhythm Association (EHRA), Heart 2 
Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and the Latin American 3 
Heart Rhythm Society (LAHRS) summarizes the consensus of the international writing group 4 
and is based on a thorough review of the medical literature regarding cognitive function in 5 
arrhythmias. The document is intended to describe the impact of different types of arrhythmias 6 
on cognitive function, to highlight possible risk markers for cognitive decline and to formulate 7 
implications for clinical practice regarding follow-up methods, prevention and treatment 8 
strategies. Our objective is to raise awareness of cognitive function among physicians treating 9 
patients with arrhythmias and to provide them with practical proposals that may lead to 10 
improvement of patient care in this regard. 11 
This document reviews terminology and the epidemiology of cognitive dysfunction, 12 
methods for assessment of cognitive function and the role of imaging. Recent studies have 13 
suggested possible associations between cognitive decline and atrial fibrillation. We review the 14 
reported literature on atrial fibrillation and cognitive function, including the scenarios of atrial 15 
fibrillation with overt stroke, silent stroke, or no stroke, and then make recommendations for 16 
assessment of cognitive function and prevention of cognitive decline in patients with AF in 17 
clinical practice.  The document also reviews the association of other arrhythmias and cognitive 18 
dysfunction, including settings such as post-cardiac arrest, cardiac implantable devices, such as 19 
implantable cardioverter-defibrillators (ICDs) and pacemakers, or ablation procedures. 20 
Implications for electrophysiological procedures and cognitive function are discussed. Long QT 21 
syndrome and cognitive function is not addressed in the document. For quick reference, sub-22 
chapters are followed by a short section on consensus recommendations. The document 23 
 7 
 
concludes with a summary of consensus statements, current knowledge gaps, and future 1 
directions of research.  2 
 3 
1.1. Evidence Review 4 
Members of the Task Force were asked to perform a detailed literature review, weigh the 5 
strength of evidence for or against a particular treatment or procedure, and include estimates of 6 
expected health outcomes for which data exist. Patient-specific modifiers, comorbidities, and 7 
issues of patient preference that might influence the choice of particular tests or therapies are 8 
considered, as are frequency of follow-up and cost effectiveness. In controversial areas, or with 9 
regard to issues without evidence other than usual clinical practice, a consensus was achieved by 10 
agreement of the expert panel after thorough deliberations. This document was prepared by the 11 
Task Force with representation from EHRA, HRS, APHRS, and LAHRS. The document was 12 
peer-reviewed by official external reviewers representing EHRA, HRS, APHRS, and LAHRS. 13 
 14 
Consensus statements are evidence-based and derived primarily from published data or 15 
determined through consensus opinion if data are not available. Current systems of ranking level 16 
of evidence are becoming complicated in a way that their practical utility might be 17 
compromised.
1
 In contrast to guidelines, we opted for an easier and user-friendly system of 18 
ranking using ‘coloured hearts’ that should allow physicians to easily assess the current status of 19 
the evidence and consequent guidance (Table 1). This EHRA grading of consensus statements 20 
does not have separate definitions of the level of evidence. This categorization, used for 21 
consensus statements, must not be considered as directly similar to that used for official society 22 
 8 
 
guideline recommendations, which apply a classification (Class I-III) and level of evidence (A, B 1 
and C) to recommendations used in official guidelines. 2 
 3 
Thus, a green heart indicates a ‘should do this’ consensus statement or indicated treatment or 4 
procedure that is based on at least one randomized trial, or is supported by strong observational 5 
evidence that it is beneficial and effective. A yellow heart indicates general agreement and/or 6 
scientific evidence favouring a ‘may do this’ statement or the usefulness/efficacy of a treatment 7 
or procedure. A ‘yellow heart’ symbol may be supported by randomized trials based on a small 8 
number of patients or which is not widely applicable. Treatment strategies for which there is 9 
scientific evidence of potential harm and should not be used (‘do not do this’) are indicated by a 10 
red heart. 11 
Table 1. Scientific rationale of recommendations*. 12 
 13 
 14 
Definitions related to a treatment or procedure Consensus statement 
instruction 
Symbol 
Scientific evidence that a treatment or procedure is 
beneficial and effective. Requires at least one 
randomized trial, or is supported by strong 
observational evidence and authors’ consensus (as 
indicated by an asterisk). 
‘Should do this’ 
 
General agreement and/or scientific evidence favour 
the usefulness / efficacy of a treatment or 
procedure. May be supported by randomized trials 
based on a small number of patients or which is not 
widely applicable. 
‘May do this’  
Scientific evidence or general agreement not to use 
or recommend a treatment or procedure. 
‘Do not do this’  
 9 
 
*This categorisation for our consensus document should not be considered as being 1 
directly similar to that used for official society guideline recommendations which apply a 2 
classification (I-III) and level of evidence (A, B and C) to recommendations. 3 
 4 
Finally, this is a consensus document that includes evidence and expert opinions from several 5 
countries. The pharmacological and non-pharmacological antiarrhythmic approaches discussed 6 
may, therefore include drugs that do not have the approval of governmental regulatory agencies 7 
in all countries. 8 
 9 
1.2. Relationships with Industry and Other Conflicts 10 
All members of the writing group, as well as reviewers, have disclosed any potential conflict of 11 
interest in detail, at the end of this document. 12 
All recommendations were voted upon by the writing committee independently and reached 13 
≥80% consensus for inclusion in recommendations tables. Each partner society officially 14 
reviewed the document and all reviewer comments were addressed. The final document and 15 
recommendations were approved by each partner society. 16 
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2. Decline of Cognitive Function: Terminology and Epidemiology 1 
 2 
2.1 Terminology: Cognitive Decline, Mild Cognitive Impairment, and Dementia 3 
Cognitive decline that is greater than expected from normal aging can be ascertained from 4 
changes in standardized cognitive test scores over time. Examples of standardized cognitive tests 5 
that evaluate different cognitive domains include Delayed Word Recall test (short-term 6 
memory),
2
 Digit Symbol Substitution test (executive function and processing speed),
3
 and Word 7 
Fluency test (executive function and expressive language).
4
 8 
Mild cognitive impairment is an intermediate stage between the expected cognitive 9 
decline of normal aging and the more serious abnormality of dementia. Mild cognitive 10 
impairment is characterized by declines in cognitive function and objective long-term cognitive 11 
deficit that does not affect activities of daily living.
5
  12 
Dementia is defined as deficits in ≥2 cognitive domains that represent a decline from 13 
previous level of functioning and that are sufficiently severe to affect activities of daily living. 14 
Both mild cognitive impairment and dementia can be further classified into subtypes.
6
 Mild 15 
cognitive impairment can be sub-typed into 4 groups (based on the scheme adopted by the 16 
National Institute on Aging Alzheimer’s Disease Centers Program for the Uniform Data Set) as 17 
amnestic or non-amnestic, single or multiple domain.
5
 Dementia can be classified into etiologic 18 
diagnoses: Alzheimer’s disease, vascular dementia, Lewy body dementia, frontotemporal 19 
dementia, and other dementias.
6
 20 
 21 
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2.2 Epidemiology of Dementia 1 
A recent systematic review provided some insights into the contemporary (1980–2009) 2 
prevalence of dementia in individuals aged ≥60 years in 21 Global Burden of Disease regions: 3 
age-standardized prevalence for those aged ≥60 years varied in a narrow band (5%–7% in most 4 
world regions), with a higher prevalence in Latin America (8.5%), and a lower prevalence in the 5 
four sub-Saharan African regions (2%–4%).7 Approximately 35.6 million people lived with 6 
dementia worldwide in 2010, with numbers expected to almost double every 20 years, to 65.7 7 
million in 2030 and 115.4 million in 2050.
7
 In 2010, 58% of all people with dementia lived in 8 
countries with low or middle incomes, with this proportion anticipated to rise to 63% in 2030 9 
and 71% in 2050.
7
 Thus, dementia is a burgeoning global public health problem that prompts an 10 
urgent and more comprehensive understanding of its risk factors with the aim to discover novel 11 
prevention strategies. 12 
The burden of dementia is rapidly increasing owing to the aging of the population. Other 13 
than advancing age, risk factors for dementia, particularly vascular dementia, have been 14 
extensively studied from an epidemiological perspective. Broadly, they can be classified as 15 
dementia due to non-modifiable risk factors, lifestyle factors, physiological risk factors, or 16 
clinical cardiovascular or cerebrovascular disease. Selected risk factors are shown in Table 2 and 17 
include many of the risk factors included in stroke risk scores in AF. 18 
 19 
Table 2. Selected Risk Factors for Dementia 20 
Non-modifiable risk factors 
Demographic factors Comments 
Age Dementia prevalence increases exponentially 
 12 
 
with age
8
 
Sex Dementia prevalence greater in women than  
men
7
 
Ethnicity VaD risk greater in blacks than whites
9
 
Genetic factors Genetic alterations may affect cognitive 
function, e.g., apolipoprotein E 4 allele and 
ABCA7 are associated with increased risk of 
AD; C9ORF72, MAPT, GRN gene mutations 
associated with frontotemporal dementia; 
rs12007229 is associated with VaD
10
 
Lifestyle factors 
Education Lower education is associated with higher VaD 
risk
11
 
Physical activity  Increased physical activity is associated with 
lower risk of general dementia, Alzheimer’s 
dementia, and VaD risk, which was attenuated 
with further adjustment for baseline cognitive, 
psychosocial, and vascular factors. Review 
reported that 7 out of 8 studies found an 
association between increased physical activity 
and lower risk of cognitive decline
12
 
Body mass index U-shaped association between body mass 
index and dementia, with dementia risk higher 
 13 
 
in individuals who were obese or 
underweight
13
 
Smoking Meta-analysis reported that current smokers 
have higher risk of cognitive decline and 
dementia over follow up, than non-smokers or 
former smokers
14
 
Social support and networks Compared with small social networks, larger 
social networks were associated with a lower 
risk of incident dementia over time.
15
 
Cardiovascular risk factors 
Blood pressure Higher mid-life blood pressure was associated 
with higher dementia risk
16
 and cognitive 
decline
17
 
Blood glucose Diabetes was associated with increased 
dementia risk
18
 and cognitive decline
19
 
Lipids Higher total serum cholesterol was associated 
with higher VaD and AD risk
20, 21
 
Clinical cardiovascular or cerebrovascular disease 
Stroke Stroke is associated with increased dementia 
risk
22, 23
 
Atrial fibrillation AF is associated with increased dementia 
risk
24, 25
 
Vascular/Peripheral arterial disease Carotid arterial disease is associated with 
 14 
 
incident dementia risk and cognitive decline
26, 
27
 
Lower ankle brachial index is associated with 
increased dementia risk
28
 
Sleep apnoea Sleep-disordered breathing is associated with 
an increased risk of cognitive impairment and a 
small worsening in executive function.
29
 
ABCA7,  ATP-binding cassette transporter A7; AD, Alzheimer’s disease; AF, atrial fibrillation; 1 
C9ORF72, chromosome 9 open reading frame 72; GRN, granulin; MAPT, microtubule-2 
associated protein tau; VaD, vascular dementia  3 
  4 
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3. Methods for Assessment of Cognitive Function 1 
Impairments of cognitive function often can be subtle and insidious, presenting as missed 2 
appointments, mislaying objects or minor problems at work or home, that are often attributed to 3 
stress, age or pressure of work. Any difference in appearance, behaviour or functioning reported 4 
by the patient or the family should alert the physician to the need for a formal assessment. The 5 
aim of this assessment is to examine higher cortical functions (attention, orientation, memory, 6 
language, praxis and executive function) from patient narrative, collateral information from 7 
families, clinical examination and standardized tests of cognitive function.
30
 For assessment of 8 
cognitive impairment a combination of tools and methods are used (Table 3). 9 
During the assessment, particular attention needs to be paid to aspects such as vagueness 10 
with dates and events, repetition, inappropriate or fixed ideas. A collateral account from a 11 
caregiver can provide clarification of symptoms and their duration. Specific areas requiring 12 
attention include features of depression, neurological or psychiatric diseases, drug/medication 13 
use, uncorrected visual and hearing problems, infections, cardiac/respiratory/renal failure or fast 14 
atrial fibrillation, all of which potentially affect cognitive function. Investigations include 15 
complete blood count, blood glucose, creatinine, electrolytes, calcium, liver and thyroid function 16 
tests, serum folate and B12 levels. Syphilis serology should be checkedin high risk patients. 17 
Magnetic resonance imaging can be helpful to estimate cerebrovascular and degenerative disease 18 
load and exclude tumours or normal pressure hydrocephalus.  19 
A list of cognitive assessment tools is provided in Table 4. Several tools are available for 20 
cognitive assessment, but there is no consensus on a preferred approach. The choice of tool 21 
should vary with the purpose of testing and other factors, such as availability, familiarity and 22 
feasibility.
31
 Common assessment tools are the two-step general practitioner assessment of 23 
 16 
 
cognition (GPCOG) and the Informant Questionnaire for Cognitive Decline in the Elderly 1 
(IQCODE), both of which have been validated in large populations.
32-34
 Standardised assessment 2 
tools are not diagnostic instruments and results need to be interpreted in the context of all 3 
available evidence. 4 
 5 
Table 3: Assessment of cognitive impairment 6 
Suspect Patient history, appearance, changes in behaviour 
Confirm Collateral history from family  
Examine Full medical examination, brief screening assessment 
Investigate Renal/liver/respiratory/thyroid compromise, B12, folate; syphilis 
serology (in high-risk patients)   
Exclude Depression, neurological/psychiatric disease, medication/drug use 
Measure Psychometric testing using validated battery 
Image Multimodal MRI (T1, T2, T2*, DWI) for brain changes 
Establish Diagnosis based on clinical + psychometric + imaging 
DWI, diffusion weighted imaging; MRI, magnetic resonance imaging 7 
 8 
Table 4: Comparison of commonly used brief cognitive assessment tools and a list of more complex 9 
cognitive assessments † 10 
 Cognitive domains assessed   
Cognitive 
assessmen
t tool 
Numbe
r of 
items 
Average 
completio
n time in 
elderly 
(≥65 
years) 
patients, 
minutes 
Equipmen
t required 
 
Memory 
V
is
u
o
sp
a
ti
a
l/
 
co
n
st
ru
ct
io
n
a
l 
p
ra
x
is
 
F
ro
n
ta
l/
 e
x
ec
u
ti
v
e 
O
ri
en
ta
ti
o
n
 
A
tt
en
ti
o
n
/ 
ca
lc
u
la
ti
o
n
 
L
a
n
g
u
a
g
e
 
In
fo
rm
a
n
t 
co
m
p
o
n
en
t 
a
Range of 
scores 
b
Cut-off 
indicating 
cognitive 
impairment 
S
em
a
n
ti
c 
S
T
M
 
R
em
o
te
 
AMT4
35
 4 1 Verbal - - + - - + - - - 
a
0-4 
CDT
36
 3 2 Pen & + - - ++ + - + - - 
a
0-3 
 17 
 
paper 
SIS
37
 6 2 Verbal - + - - - + - - - 
a
0-6 
b≤337 ≤438 
Mini-
Cog
39
 
6 3 Pen & 
paper 
+ + - ++ + - + - - 
a
0-5 
b
<4 
AMT
35
 10 3 Verbal + + + - - ++ ++ - - 
a
0-10 
b
<8 
MIS 
40
 4 4 Verbal - + - - - - - - - 
a
0-8 
b≤4 
6CIT
41
 6 5 Verbal - ++ - - - ++ ++ - - 
a
0-28 
b≥8 
GPCOG
42
 
9 5-6 Pen & 
paper 
+ ++ - ++ + + + - + 
a
0-9 
b
0-4; 5-8 
proceed 
with InQ 
MMSE*
43
 
30 8 Pen, 
paper, & 
watch 
- + - + - +++ ++ ++ - 
a
0-30 
b
<24 
(≤23 
if ≤12 
years 
education; 
≤25 if 
higher 
education) 
MOCA
4
4
 
30 10 Pen & 
paper 
- ++ - +++ ++ +++ ++
+ 
++
+ 
- 
a
0-30 
b
<26; add 
1 point if 
≤12 years 
education 
OCS
45
 10 
tasks 
15-20 Pen & 
paper 
+ ++
+ 
++ +++ +++ +++ ++
+ 
++
+ 
- 
a
-1 to 111
 
ACE
46
 100 20 Pen, 
paper, 
watch & 
specific 
pictures 
++ ++
+ 
++ +++ ++ +++ ++ ++
+ 
- 
b
<87 
More complex and extended cognitive examinations‡  
3MS
47
: extension of MMSE including verbal fluency and further memory testing; overall score 0-100; score <78 
for those aged ≥65 years 
CAMCOG
48
: 80 mins, structured history taking from patient and informant, structured examination and mental 
state assessment 
CASI
49
: questions form MMSE and 3MS; scored 0-100 takes 15-20 minutes to complete 
IQCODE
50
: 16-item informant questionnaire comparing patient cognition now to 10-years ago; each rated on 5-
point Likert scale 
3MS, Modified Mini Mental Status Examination; 6CIT, 6-item Cognitive Impairment Test; ACE, Addenbrooke’s Cognitive 1 
Examination; AMT, Abbreviated Mental Test; CAMCOG, Cambridge Cognitive Examination; CASI, Cognitive Abilities 2 
Screening Instrument; CDT, Clock Drawing Test; GPCOG, General Practitioner Assessment of Cognition; InQ, Informant 3 
 18 
 
Questionnaire; MMSE, Mini Mental State Examination; MIS, Memory Impairment Screen; MOCA, Montreal Cognitive 1 
Assessment; OCS, Oxford Cognitive Screen; SIS, Six-Item Screener; STM, short-term memory;  *Standardised MMSE is 2 
also available; †adapted from Woodford & George51; ‡ not an exhaustive list 3 
- not specifically tested 
+ minimal assessment 
++ moderate assessment 
+++ relatively extensive assessment 
  4 
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4. Role of Imaging 1 
Brain imaging studies can identify vascular disease as a cause of dementia. In an autopsy study 2 
of patients with dementia, pathologic diagnoses implicated vascular disease in about 25% of 3 
subjects, half of whom had pure vascular disease.
52
 The three main causes of vascular cognitive 4 
impairment (VCI) are large vessel strokes, small vessel disease (SVD), and micro-haemorrhages. 5 
The preferred imaging modality, magnetic resonance imaging (MRI), has high specificity and 6 
sensitivity for detecting these changes and is an important adjunct to clinical and psychometric 7 
assessments. However, imaging findings need to be interpreted in the clinical context because of 8 
uncertain correlation with symptoms or psychometric test performance.
53
  9 
Structural imaging is undertaken using T1- and T2-weighted spin echo sequences to 10 
identify infarcts and macro-haemorrhages, T2*- weighted gradient echo sequences for micro-11 
haemorrhages, fluid-attenuated inversion recovery (FLAIR) imaging for incomplete infarcts and 12 
leukoaraiosis and diffusion weighted imaging (DWI) for visualising the integrity of functional 13 
network fibre tracts not captured by other imaging techniques. MRI provides several markers of 14 
micro- and macrostructural organization that are sensitive to change, related to clinical endpoints 15 
and has the potential to predict cognitive trajectories in individual patients. 
53
   16 
MRI signs that predict potential cognitive impairments include a) large or bilateral 17 
infarcts due to large vessel disease; b) strategic infarcts secondary to embolization in regions as 18 
hippocampus, dominant thalamus, medial temporal, deep frontal; c) lacunes, white matter hyper-19 
intensities (leukoaraiosis) and haemorrhages associated with small vessel disease; and d) lobar 20 
micro-haemorrhages representative of amyloid angiopathies. In addition, although global 21 
cerebral atrophy and/or medial-temporal lobe atrophy may suggest an element of Alzheimer’s 22 
 20 
 
Disease (mixed cognitive impairment), subcortical infarcts, per se, may trigger progressive focal 1 
thinning and grey matter atrophy in connected temporal and frontal cortical areas.
31
 2 
Imaging of cerebral blood flow using arterial spin labelling (ASL), metabolic imaging 3 
with proton magnetic resonance spectroscopy (1H-MRS) and dynamic contrast-enhanced MRI 4 
(DCEMRI) can help estimate the extent of injury, vessel permeability and inflammation. 5 
Although these can differentiate between dementias and separate pathological changes from 6 
those due to aging, they remain research techniques with limited clinical application.  7 
PET scans have also been used to assess brain metabolic function, inflammation, amyloid or tau 8 
protein, which may be helpful in differentiating some types of dementia.
53
An overview of 9 
commonly used imaging modalities in cognitive impairment is provided in Table 5.  10 
 11 
Table 5: Commonly used brain imaging modalities in cognitive impairment 12 
Modality Use 
CT  Large infarcts/haemorrhage, established small vessel disease, other 
pathologies, limited application  
MRI Imaging of choice for assessment of cognitive impairment
54
 
 T1 & T2 MRI Highly sensitive to old and new infarcts, estimation of white matter 
disease load, other pathologies (e.g. malignancies, cerebral oedema) 
 T2* MRI Blood and blood products (e.g. haemorrhages), micro-haemorrhages, 
haemosiderin deposition, amyloid angiopathies 
 DWI MRI Extremely sensitive to early ischaemic changes (recent infarcts 
including micro-infarcts), integrity of fibre tracts, extensively used for 
tractography assessing the structural integrity of connecting white 
 21 
 
matter tracts) 
 1H-MRS Measurement of neuronal damage, inflammation, gliosis, 
differentiation between pathology and normal aging 
 1H-MRS: Proton magnetic resonance spectroscopy; CT: computed tomography; DWI: Diffusion 1 
weighted imaging; MRI: magnetic resonance imaging  2 
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5. Atrial fibrillation and cognitive function 1 
5.1 Atrial fibrillation, overt stroke and cognitive function 2 
Evidence suggests that atrial fibrillation (AF) is associated with a higher risk for cognitive 3 
impairment and dementia, with or without a history of clinical stroke. Two meta-analyses that 4 
included both cross-sectional and prospective studies specifically examined the incidence of 5 
dementia in patients with AF and strokes.
24, 25
 These meta-analysesfound similar estimates of the 6 
risk ratios of cognitive impairment or dementia of 2.43
24
 and 2.70
25
 (Table 6).  7 
It is uncertain whether or not risk of cognitive impairment and dementia vary by 8 
paroxysmal versus persistent AF. Many of the studies examining AF type were small and 9 
underpowered and the factors that impact progression, such as rhythm control approaches and 10 
physician approach to the patient management, can introduce study biases. In a small hypothesis 11 
generating cross-sectional study from the Atherosclerosis Risk in Communities Cohort
55
 12 
persistent but not paroxysmal AF classified by ambulatory telemetry monitoring was associated 13 
with lower cognitive function. Another small cross-sectional study reported that cognitive 14 
performance did not significantly differ by AF burden, but the number of subclinical cerebral 15 
ischemia areas was higher in individuals with persistent compared to paroxysmal AF.
56
 More 16 
conclusive understanding of the relation of AF burden to cognitive decline and dementia will 17 
require larger and longitudinal studies. The relation between AF type and cognitive impairment 18 
and dementia is further complicated by the sometimes arbitrary definition of the AF type in the 19 
individual patient. 20 
Unfortunately there are no randomized data examining the efficacy of therapies and in 21 
particular of individualised management to prevent dementia in individuals with AF.
57
 Of 22 
interest, the Framingham Heart Study has examined temporal trends in the incidence of dementia 23 
 23 
 
and noted that the risk of dementia associated with AF declined over 3 decades (1970s to the 1 
early 2010s).
58
 One speculation is that improved anticoagulation and treatment of risk factors 2 
were responsible for the declining incidence of dementia in individuals with AF. Another piece 3 
of inferential evidence, supporting the benefit of preventing stroke as a strategy to prevent 4 
dementia in individuals with AF, are observational meta-analyses (Table 6). In individuals with 5 
AF but without stroke at baseline the risk of dementia and cognitive decline is more modest 6 
(relative risk (RR) 1.37, 95% CI 1.08 to 1.73) than in individuals with both AF and a history of 7 
stroke (RR 2.7, 95% CI 1.82 to 4.00).
25
 8 
Systemic anticoagulation remains the cornerstone of stroke prevention treatment. By 9 
meta-analysis, adjusted-dose warfarin is associated with a 64% (95% CI 49 to 74%) significantly 10 
lower risk of stroke (Table 7), whereas aspirin alone was associated with a 19% (95% CI -1 to 11 
35%) non-significant lower stroke risk.
59
 In studies comparing warfarin and aspirin, warfarin was 12 
associated with a 38% (95% CI 18 to 52%) stroke reduction, when compared to aspirin alone.
59
 13 
A meta-analysis of the 4 randomized trials comparing the non-vitamin K antagonist oral 14 
anticoagulants (NOACs) to warfarin, demonstrated that the NOACs were associated with a 15 
significant risk reduction (RR 0.81, 95% CI 0.73 to 0.91) in overall stroke and systemic emboli, 16 
in part driven by the significant risk reduction (RR 0.48, 95% CI 0.39 to 0.59) in haemorrhagic 17 
stroke.
60
  18 
Since a prior stroke represents the strongest predictor of stroke recurrence, all patients 19 
who have AF and have had an ischemic stroke, should be anticoagulated, unless an absolute 20 
contraindication exists.
61
 Of interest, a recent observational study using a propensity score 21 
matched analysis reported that in individuals with a history of AF and dementia, persistent use of 22 
warfarin therapy was uncommon (16%), but was associated with the prevention of stroke (HR, 23 
 24 
 
0.74; 95% CI, 0.54– 0.996; P=0.047) and death (HR, 0.72; 95%CI, 0.67-0.87; P<0.001).62 A 1 
recent updated metaanalysis reported a significant reduction of stroke, stroke or systemic 2 
embolism, hemorrhagic stroke, and intracranial bleeding in AF patients with previous stroke or 3 
transient ischemic attack receiving NOACs compared with warfarin.
63
 4 
 5 
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Table 6. Meta-analyses relating atrial fibrillation to dementia and cognitive impairment  
Author, year Study design Outcome Inclusions/exclusions Risk  
Kwok et al., 
2011
24
 
Meta-analysis cross-sectional 
and prospective studies 
Dementia Patients with H/o stroke 
7 studies; N=2425 
OR, 2.43; 95% CI, 1.70-3.46; p<0.001; 
I
2
=10% 
Kalantarian, 
et al. 2013
25
 
Meta-analysis cross-sectional 
and prospective studies 
Cognitive impairment 
& dementia 
Patients with H/o stroke  
7 studies; N=2409 
RR, 2.70; 95% CI, 1.82-4.00;  
I
2
=32.3%; p=0.18 
   Excluding patients with 
or adjusting for H/o 
stroke 10 studies 
RR, 1.34; 95% CI, 1.13-1.5 
H/o: history of; OR: Odds Ratio; RR: Relative Risk 
 
Table 7. Meta-analyses examining anti-coagulation strategies in atrial fibrillation relating to stroke 
Author, year Study design Outcome Inclusions/exclusions Risk  
Hart, et al. 
2007
59
 
Meta-analysis adjusted dose 
warfarin & aspirin 
Stroke 6 RCTs Warfarin vs. 
Placebo 
N=2900 
RR, 64% reduction; 95% CI, 49-74% 
Absolute reduction:  
1
o
 prevention 2.7%/yr 
 26 
 
2
o
 prevention 8.48%/yr 
   7 RCTs Aspirin vs. 
Placebo or no Rx 
N=3900 
RR, 19% reduction; 95% CI, -1 to 35% 
1
o
 prevention 0.8%/yr 
2
o
 prevention 2.5%/yr 
   8 RCTs Warfarin vs.  
aspirin Rx 
N=3647 
RR, 38% reduction; 95% CI, 18-52% 
1
o
 prevention 0.7%/yr 
2
o
 prevention 7.0%/yr 
Ruff, et al. 
2014
60
 
Meta-analysis  
Phase 3 RCTs:   
Stroke & Systemic 
Emboli 
n=29,312 NOAC;  
n=29,272 Warfarin 
RR, 0.81; 95% CI, 0.73–0.91; 
p<0·0001;  
I
2
=47%; p=0.13 
 RE-LY,  
ROCKET AF,  
ARISTOTLE,  
ENGAGE AF–TIMI 48 
 N=41257, no Prior 
stroke 
N=17269, Prior Stroke 
RR, 0.85; 95% CI, 0.72–1.01 
RR, 0.89; 95% CI, 0.77–1.02) 
Pinteraction=0.30 
  Ischaemic stroke n=29,292 NOAC;  
n=29,221 Warfarin 
RR, 0.92; 95% CI, 0.83-1.02; p=0.10 
I²=32%; p=0.22 
 27 
 
  Haemorrhagic stroke n=29,292 NOAC;  
n=29,221 Warfarin 
RR, 0.49; 95% CI, 0.38–0.64; p<0·0001 
I²=34%; p=0.21 
H/o: history of; NOAC: Non-Vitamin K Antagonist Oral Anticoagulant; RCT: Randomized Clinical Trial; RR: Relative Risk 1 
 28 
 
5.2 Atrial Fibrillation, Silent Stroke and Cognitive Function  1 
It is well established that AF increases the risk of clinical stroke by four- to five-fold, and 2 
patients with a clinical history of stroke are at increased risk of developing dementia.
64-67
 3 
However, AF is also associated with cognitive dysfunction ranging from mild impairment to 4 
overt dementia, independently of clinical stroke as well as multiple shared risk factors.
64, 67
 It is 5 
also well established that AF and cognitive impairment share common risk factors, including 6 
advanced age, diabetes, hypertension, sleep apnoea and chronic heart failure. Moreover, data 7 
have demonstrated a significant (34%) increase in the risk of cognitive impairment in patients 8 
with AF in the absence of clinical stroke, even after adjustment for shared risk factors.
64,
 
25 Thus, 9 
additional mechanisms beyond clinically recognized stroke and shared risk factors may link AF 10 
and cognitive impairment. One of the leading potential mechanisms is the occurrence of silent 11 
cerebral infarcts, which occur significantly more frequently than clinical stroke and are 12 
particularly common in patients with AF. 
68, 69
  13 
Detection of cerebral ischemic events on MRI is based on acute hyperintense lesions on 14 
diffusion-weighted imaging. Brain MRIs reveal evidence of silent cerebral infarcts in a 15 
significant percentage of patients with AF.
69
 The incidence is related to specifications of MRI 16 
and depends on the definition applied.
70
 AF is associated with a more than two-fold increase in 17 
the risk of developing silent cerebral infarcts.
69
 Although silent infarcts are not associated with 18 
clinically apparent acute neurologic deficits, data suggest a significant association between silent 19 
infarcts and the development of cognitive decline and dementia.
71-73
 Silent infarcts in patients 20 
with AF are believed to be micro-embolic in origin and are identified as small, well-demarcated 21 
lesions, often in clusters, and are most prevalent in the frontal lobes.
71
 The pattern of silent 22 
infarct distribution is similar to that seen in vascular dementia, in which most silent strokes affect 23 
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frontal circuit components (frontal cortex, basal ganglia, thalamus) that play an important role in 1 
executive functioning.
74
 Thus, the term “silent infarct” is probably a misnomer. Because of their 2 
small size and location away from speech and motor centres, these micro-injuries do not cause 3 
clinically apparent acute focal neurological deficits. However, with the accumulation of silent 4 
infarcts and associated repetitive brain injuries over time, micro-injuries may contribute to the 5 
development of cognitive impairment. At least one study has specifically addressed the role of 6 
subclinical cerebrovascular disease as a mediator between AF and cognitive impairment. In a 7 
subset of stroke-free participants in the Atherosclerosis Risk in Communities (ARIC) study who 8 
underwent repeat brain magnetic resonance imaging after approximately 12 years, AF was 9 
associated with cognitive decline only in those patients who had developed incident silent 10 
cerebral infarcts.
75
 11 
There is a paucity of evidence regarding the effect of anticoagulation on silent cerebral 12 
infarcts and the risk of cognitive impairment. One recent study addressed this issue by evaluating 13 
the time in therapeutic range (TTR) as an indicator of the effectiveness of warfarin 14 
anticoagulation in patients with AF. These investigators observed a consistent increase in the risk 15 
of dementia as the percentage of TTR decreased.
76
 The association between warfarin therapy and 16 
dementia was “U”-shaped, with increased risk of dementia among patients with overexposure 17 
and underexposure to warfarin (i.e., supra-therapeutic and sub-therapeutic international 18 
normalized ratios [INRs]).
76
 This may be due to cumulative brain injury from cerebral micro-19 
bleeds and silent infarcts, respectively. Recent observational data also suggest that delaying 20 
warfarin therapy in patients with AF and no history of dementia, including patients at low as well 21 
as high risk for stroke, significantly increases the risk for developing incident dementia.
12, 77
 22 
Whether the use of the NOACs will offer greater protection than warfarin in preventing AF-23 
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related cognitive impairment and dementia remains to be determined. The significantly lower 1 
intracranial haemorrhage and microhemorrhage rates,
78
 the lower risk of mortality with 2 
intracranial haemorrhage with use of NOACs compared to warfarin,
79
 coupled with comparable 3 
degrees of protection against thromboembolic stroke and substantially lower variability in 4 
therapeutic anticoagulation effect over time with NOACs, offer reasons to hypothesize that these 5 
agents may be advantageous to warfarin regarding protection against cognitive impairment in 6 
patients with AF but this requires confirmation. Initial findings seem to confirm this 7 
hypothesis.
80
 8 
 9 
5.3 Atrial Fibrillation and Cognitive Function in the Absence of Stroke 10 
Longitudinal studies have shown that dementia is more common in patients diagnosed with AF
81, 
11 
82
 even in the absence of stroke. A meta-analysis of 8 prospective studies evaluating the 12 
relationship between AF and incident dementia in patients without stroke and baseline normal 13 
cognitive function included a total of 77,668 patients of whom 15% had AF. After a mean 14 
follow-up of about 8 years, 6.5% of patients developed dementia. AF was independently 15 
associated with increased risk of incident dementia (HR 1.42 95% CI 1.17-1.72, p<0.001)
83
. This 16 
result was confirmed by a longitudinal analysis from the Cardiovascular Health Study including 17 
5,150 participants without baseline history of stroke
84
. Incident AF occurred in 11% of patients, 18 
with faster decline in mean cognitive function scores, measured using the Modified Mini Mental 19 
State Exam (3MSE), compared with patients in sinus rhythm. Although both AF and dementia 20 
are diseases of aging, in two large observational studies the highest relative risk of dementia was 21 
observed in younger AF patients <70 years of age
85, 86
. A recent cross-sectional study indicated 22 
that in individuals with heart failure with reduced and preserved systolic ejection fraction, AF 23 
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was associated with an adjusted higher odds of presence and severity of prevalent cognitive 1 
impairment.
87
 However, in very old individuals (≥80 years) the relationship between AF and 2 
dementia seems to be mostly mediated by concomitant risk factors.
88
 3 
The relationship between AF and cognitive decline may occur through a variety of 4 
pathological mechanisms.  Given the relationship between AF and stroke, vascular dementia may 5 
be an obvious contributor to cognitive decline, encompassing both multi-infarct dementia and 6 
small vessel disease dementia
81-84, 89. The second form of dementia in AF patients is Alzheimer’s 7 
disease, which is the most common type of dementia overall. AF has been identified as a risk 8 
factor for Alzheimer’s disease85, 90. Alzheimer’s disease is the result of accumulation of 9 
abnormally folded beta-amyloid and tau proteins forming cerebral plaques which exert cytotoxic 10 
effects leading to cerebral atrophy. Interestingly, misfolded atrial natriuretic peptides may lead to 11 
development of amyloid fibrils and deposits in the atria of elderly patients with AF causing a 12 
specific atrial cardiomyopathy classified as EHRAS IVa
91, 92. However, if AF and Alzheimer’s 13 
disease share a common link with regards to protein misfolding and amyloidgenesis, it does not 14 
appear to be through the APOE ε4 allele93. Other studies suggest that the occurrence of 15 
Alzheimer’s disease is related to hypoperfusion, inflammation, oxidative stress and endothelial 16 
dysfunction
94-96
. All these factors may be induced by several non-cardiac diseases resulting in an 17 
atrial cardiomyopathy which in turn, leads to AF
92
 in the sense of both AF and Alzheimer's 18 
disease being the result of third confounding factors. Additionally, several circulating biomarkers 19 
of oxidative stress, inflammation and endothelial dysfunction are elevated during AF
92, 97, 98
. 20 
These factors are also linked to cerebral small vessel disease; therefore, AF may provide a 21 
specific milieu for non-stroke related cognitive decline and dementia. For example, hippocampal 22 
atrophy in AF patients may be mediated by altered cerebral perfusion due to irregular RR 23 
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intervals, abnormal or rapid heart rate, and reduced blood pressure caused by AF, since the 1 
hippocampus is one of the most perfusion-sensitive structures of the brain
95, 99-102
.  2 
Interestingly, patients with AF had lower total brain volume compared to those without 3 
AF, independent of cerebral emboli in a large cross sectional study
103
. In addition, recently, AF 4 
was associated with a decrease in total cerebral blood flow and brain perfusion in an unselected 5 
elderly cohort
104
. These results may, at least in part, explain the association of AF with reduced 6 
relative brain volume and cognitive impairment. 7 
 8 
A schematic overview of the various mechanisms, through which AF may lead to 9 
cognitive impairment is illustrated in Figure 1. 10 
A number of trials are currently examining, as the primary or secondary outcome, the 11 
effect of different therapies including anticoagulation and of different interventions on cognitive 12 
function in patients with AF. A non-exhaustive list of such studies is found in Table 8:  13 
 14 
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Table 8: Studies that are currently examining the effect of different therapies and interventions on cognitive function in patients with 1 
AF or atrial tachyarrhythmias 2 
Study name Target population Intervention Cognitive function as 
outcome 
Impact of Anticoagulation Therapy on the 
Cognitive Decline and Dementia in Patients With 
Non-Valvular Atrial Fibrillation (CAF), 
NCT03061006 
Non-valvular AF Randomization to 
Dabigatran or Warfarin 
Primary outcome: incident 
dementia and moderate decline 
in cognitive function 
Comparison of Brain Perfusion in Rhythm Control 
and Rate Control of Persistent Atrial Fibrillation, 
NCT02633774 
Persistent AF Randomization to rhythm 
or rate control 
Primary outcome: cognitive 
assessment 
Cognitive Impairment Related to Atrial Fibrillation 
Prevention Trial (GIRAF), NCT01994265 
AF patients > 65 years old 
and CHA2DS2-VASc > 1 
Randomization to 
Dabigatran or Warfarin 
Primary outcome: cognitive 
impairment  
Early Treatment of Atrial Fibrillation for Stroke 
Prevention Trial (EAST), NCT01288352 
AF patients Randomization to early 
standardised rhythm 
control or usual care 
Secondary outcome: cognitive 
function 
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Apixaban During Atrial Fibrillation Catheter 
Ablation: Comparison to Vitamin K Antagonist 
Therapy (AXAFA), NCT02227550 
Patients undergoing 
catheter ablation of non-
valvular AF 
Randomization to Vitamin 
K antagonists or Apixaban 
Secondary outcome: cognitive 
function change 
NOACs for Stroke Prevention in Patients With 
Atrial Fibrillation and Previous ICH (NASPAF-
ICH), NCT02998905 
Patients with a high-risk of 
AF and previous 
intracerebral hemorrhage 
Randomization to non-
Vitamin-K-antagonist oral 
anticoagulant or 
acetylsalicylic acid 
Secondary outcome: cognitive 
function 
Non-vitamin K Antagonist Oral Anticoagulants in 
Patients With Atrial High Rate Episodes (NOAH), 
NCT02618577 
patients with atrial high 
rate episodes and at least 
two stroke risk factors but 
without AF 
Randomization to 
edoxaban or acetylsalicylic 
acid or placebo 
Secondary outcome: cognitive 
function 
Optimal Anticoagulation for Higher Risk Patients 
Post-Catheter Ablation for Atrial Fibrillation Trial 
(OCEAN), NCT02168829 
Patients having undergone 
a successful AF catheter 
ablation 
Randomization to 
rivaroxaban or 
acetylsalicylic acid 
Secondary outcome: 
neuropsychological testing 
Blinded Randomized Trial of Anticoagulation to 
Prevent Ischemic Stroke and Neurocognitive 
Patients with non-valvular 
AF and with low risk of 
Randomization to 
rivaroxaban or 
Primary outcome: Composite 
endpoint of stroke, TIA and 
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Impairment in AF (BRAIN-AF), NCT02387229 stroke acetylsalicylic acid neurocognitive decline 
Secondary outcomes: 
Neurocognitive decline, new 
onset of cognitive impairment 
 1 
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The results of these studies will help to improve our understanding of the relationship 1 
between AF and cognitive function and provide us with more data for possible prevention of 2 
cognitive decline by treatment of AF. 3 
It has also to be noted that conversely, impairment of cognitive function per se might 4 
have a negative impact on therapy adherence, medication intake
105, 106
 and may thus adversely 5 
affect treatment effectiveness and outcome in patients with arrhythmias.  6 
 7 
5.4 Assessment of Cognitive Function in Atrial Fibrillation Patients in Clinical Practice 8 
Despite increasing awareness about the relationship between AF and cognitive decline
75, 99, 107, 
9 
108
, clinical guidelines for the management of AF do not specifically include assessment of 10 
cognitive function in the diagnostic work-up.  With increasing prevalence of cognitive 11 
impairment in the elderly
109
 and given that the highest relative risk of cognitive decline is in AF 12 
patients >70 years of age, healthcare professionals who treat AF patients should be able to 13 
diagnose, and assess risk factors for cognitive impairment appropriately. 14 
Assessment of cognitive function should be multifaceted (see Table 3), and psychometric 15 
testing is just one component.  Numerous validated tools are available to assess cognitive 16 
function, varying from brief screening tools, which take 1-8 minutes to complete among elderly 17 
patients, to more complex time-consuming neuropsychological batteries (see Table 4). Brief 18 
screening tools may be most applicable when cognitive impairment is suspected among AF 19 
patients, whereas more comprehensive assessments may be performed after appropriate referral 20 
to a geriatrician or neurologist. Other factors determining the choice of test include the time 21 
available with the patient, the setting (office-based or inpatient), the patient’s ability to speak 22 
English (some tools are not translated and/or validated in other languages), and the purpose of 23 
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the assessment (screening versus confirmatory).  In practical terms, any of the brief tests could 1 
be used, although the most common is the GPCOG
42
. In research settings, the Mini Mental State 2 
Examination (MMSE) and Montreal Cognitive Assessment (MOCA) have been commonly 3 
used
43, 44, 110
. Informant questionnaires, such as the second step of GPCOG or the IQCODE
50
, 4 
provide important additive information, since they assess a patient’s change over time from 5 
someone who knows the person well.  This level of detail may not always be feasible, however, 6 
and may be more suited for comprehensive geriatric or neurological assessment. 7 
 8 
5.5 Prevention of Cognitive Dysfunction in Atrial Fibrillation Patients 9 
Since the precise mechanism(s) of cognitive disorders in patients with AF is not fully known, the 10 
optimal way to prevent cognitive dysfunction for a given patient remains to be established.  11 
Considering the mechanisms of cognitive impairment described in the sections above, several 12 
therapies may be considered (see “Recommendations”). Both disease states share common risk 13 
factors that include aging, smoking, hypertension, diabetes, sleep apnoea, physical inactivity, 14 
vascular disease, inflammation, and heart failure. Many of these risk factors represent modifiable 15 
targets for preventative therapies and if treated early may lower the risk of both diseases. 16 
Stroke prevention is the principal priority in the management of AF and integrated 17 
approaches such as the Atrial fibrillation Better Care (ABC) pathway (Avoid stroke, Better 18 
symptom management, Cardiovascular and comorbidity risk reduction) may improve AF 19 
management
111
. Stroke prevention therapy, particularly oral anticoagulation, applied to the 20 
appropriate patients according to risk stratification proposed in scientific guidelines
108
 may 21 
reduce the risk of dementia. Fridberg and Rosenqvist studied 444,106 AF patients over 1.5 22 
million years at risk. Anticoagulation use was in 202,946 (46%) of the patients with the primary 23 
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anticoagulant used warfarin (94%)
112
. In AF patients not treated with anticoagulation, 60% were 1 
on aspirin. In multivariate analysis, the strongest predictors of dementia were in order: age 2 
(hazard ratio (HR) per decade 2.19, 95% CI 2.16–2.22), Parkinson’s disease (HR 2.46, 95% CI 3 
2.25–2.69), absence of oral anticoagulation treatment (HR 2.08, 95% CI 1.73–2.53), and alcohol 4 
abuse (HR 1.53, 95% CI 1.41–1.66). 5 
In patients managed long term with vitamin K antagonists, for example, TTR is inversely 6 
associated with new-onset dementia
76
. Risk of dementia is augmented in AF patients who are 7 
frequently over anticoagulated or receiving antiplatelet therapy
113
.  However, dementia can have 8 
a confounding effect on maintenance of TTR, and oral anticoagulation in AF patients has not 9 
been consistently associated with either improved cognitive function or less hippocampal 10 
atrophy
99, 110, 114
. Anticoagulation with warfarin neither influenced the reduction of total brain 11 
volume nor cognitive function in individuals with AF 
103
. NOAC therapy may reduce the 12 
incidence of brain micro-haemorrhage compared to vitamin K antagonists
60
, but whether NOACs 13 
improve long-term cognitive function is currently unknown.  A recent community-based study 14 
provided some optimism in this regard and found that NOAC therapies were associated with 15 
lower stroke and dementia rates compared to warfarin
115
. Considering the incidence of dementia 16 
in AF, only trials with large numbers of patients and extended long-term follow-up would be 17 
able to firmly establish the possible benefit of oral anticoagulation on the subsequent risk of 18 
cognitive decline. 19 
Preventing early onset of AF through lifestyle or risk factor modification could delay the 20 
onset and progression of cognitive decline. Prevention and early management of smoking, excess 21 
alcohol consumption, hypertension, obesity, diabetes, and sleep apnoea may reduce the onset 22 
and/or progression of AF
116
 with concomitant reductions in stroke and possibly cognitive 23 
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function. However, such risk factor modifications may have independent positive effects on 1 
cognitive function regardless of the development of AF. It is also unclear if aggressive 2 
modification should start at the time of onset of AF. Lifestyle modification may also reduce the 3 
risk of cognitive decline in AF patients. Prevention of cognitive dysfunction may include general 4 
measures proposed in the treatment and management of vascular dementia or Alzheimer’s 5 
disease. Several trials have tested the effects of physical activity and cognitive training in 6 
Alzheimer’s disease and have shown some evidence of efficacy on cognitive endpoints117. Most 7 
of the trials, however, had short follow-up periods.  Further evidence is needed to confirm the 8 
optimal design and dose of interventions, the appropriate target population, and the efficacy of 9 
such interventions.  Innovations such as the development of multi-domain interventions and the 10 
use of biomarkers or genetic profiles to better target higher-risk patients are being assessed in 11 
ongoing trials.  However, differentiating the AF-dependent or AF-independent effects of lifestyle 12 
and risk factor modifications remains a major challenge. 13 
There are no robust data to affirm that therapy for rhythm control with medication or 14 
"successful" AF catheter ablation can prevent cognition disorders in AF patients. AF catheter 15 
ablation may not eliminate AF in the majority of patients, but rather attenuate overall AF burden.  16 
Follow-up data beyond 5 or 10 years are limited, and suggest that 2-5% of “successfully” ablated 17 
patients will have recurrences annually 
118-121
. Furthermore, many of these recurrences may be 18 
asymptomatic and the prognostic implication of asymptomatic episodes on both stroke risk and 19 
cognitive function is unknown
122-124
. Catheter ablation as a specific therapeutic approach to 20 
lower risk of stroke and dementia is discussed in the section “Catheter Ablation”. 21 
In patients with persistent AF for whom which rhythm control is not pursued, AV node 22 
ablation with pacemaker implantation that restores a predictable R-R interval and heart rate has 23 
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been shown, in a small study, to improve frontal and temporal blood flow and improve memory 1 
and learning
125
. 2 
Recommendations on the prevention of cognitive dysfunction in AF patients are made in 3 
the section “Recommendations”. Most of these recommendations are consistent with those of 4 
international guidelines
108
 and are not necessarily unique to those patients with AF and cognitive 5 
dysfunction.   6 
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6. Other arrhythmias and cognitive dysfunction 1 
 2 
6.1 Cognitive dysfunction in patients with regular supraventricular tachycardias 3 
Recurrent supraventricular tachycardias in children and adolescents, mediated by AV nodal 4 
reentry or by accessory pathways, were shown to be associated with cognitive deficits in 48% of 5 
such patients, when assessed prior to catheter ablation.
126
 Whether an early catheter ablation of 6 
supraventricular arrhythmia would affect the cognitive status of such patients needs further 7 
investigation. 8 
6.2 Cognitive impairment after cardiac arrest 9 
Brain injury after non-fatal cardiac arrest. 10 
Cardiac arrest occurs in two different settings, in-hospital and out-of-hospital, with completely 11 
different prognosis, for obvious reasons:. As cardiac arrests that occur in a hospital context are 12 
usually immediately attended, the primary focus of the study of brain injury after cardiac arrest 13 
has been among survivors of out-of-hospital cardiac arrest (OHCA).
127
 In this setting, brain 14 
damage is caused by cerebral hypoperfusion and its severity depends on the time of such 15 
deficit;
128
 the proportion of cardiac arrest survivors who present with some degree of brain 16 
damage ranges from 35% to 100%.
129, 130
 The working group of Chun-Lim and colleagues has 17 
delineated 3 scenarios that are clearly related to the duration of brain hypoperfusion: 1) patients 18 
with early recovery of brain function without any sequelae, usually associated with opportune 19 
resuscitation and/or early recovery of consciousness (less than 3 days after OHCA); 2) patients 20 
with extensive damage, associated with prolonged coma (more than 7 days after OHCA); and 3) 21 
an intermediate group between those extremes.
131
 They report that a coma duration of less than 3 22 
days results in a better quality of life at 3 and 12 month follow-up, and that the manifestation of 23 
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severe cognitive impairment early on in recovery results in higher risk for permanent memory 1 
and motor impairment. 2 
Clinical sequelae of brain damage after OHCA may range from mild memory impairment 3 
to severe physical and mental disability. As expected, if brain damage persists, it negatively 4 
impacts patients’ quality of life.131, 132 Cognitive impairment could include limited attention span, 5 
personality disturbances, movement disorders (i.e. Parkinsonism), and even dementia; however, 6 
memory seems to be the cognitive function most affected in survivors of cardiac arrest. 7 
Neuropsychological studies have shown deficits in different cognitive areas including memory 8 
(64.3%), executive functioning (21.4%), language (21.4%), and perception (14.3%).
133
 In 1990, 9 
the Utstein style was developed in order to standardize the results of resuscitation studies; this 10 
includes neurological evaluation using either the Cerebral Performance Category (CPC) or the 11 
Modified Rankin Scale (mRS).
134, 135
 CPC classifies patients on a scale from 1 to 5 (1= good 12 
cerebral performance; 5= deceased) while the mRS classifies patients on a 0 to 6 scale (0= 13 
asymptomatic; 6= deceased); CPC scores of 1-2 and mRS scores of 0-3 are considered 14 
favourable neurological outcomes.
135
 These criteria are included as a reminder of the risk of 15 
neurological dysfunction among survivors of cardiac arrest. 16 
 17 
Memory impairment after cardiac arrest. 18 
In patients successfully treated for an OHCA in a rapid emergency response program, the long-19 
term survival and quality of life are similar to age- and gender-matched controls.
136
 However, if 20 
cognitive assessment is evaluated in detail, memory loss is prevalent.
137
 Alexander et al. reported 21 
that among 30 selected patients (1 day of coma, with responsiveness after 24 hours but with 22 
remaining confusion for 7 days), only one third of the sample suffered from motor impairment 23 
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after the event, but the total population showed at least a mild degree of memory impairment.
138
 1 
Torgersen et al. also reported that even after therapeutic hypothermia, 52% of the patients who 2 
suffered cardiac arrest showed cognitive impairment, especially episodic memory dysfunction.
139
 3 
This finding is not new, in 1996, Grubb et al. demonstrated in a population of 35 patients that up 4 
to 37% of the patients suffered chronic memory impairment after cardiac arrest, and that memory 5 
dysfunction was inversely proportional to the duration of the event.
140
 6 
Memory impairment after cardiac arrest does not seem to improve over time; a case-7 
control study comparing OHCA patients with patients who suffered acute coronary syndrome 8 
without OHCA (controls) showed that memory impairment recorded at 3 month follow-up 9 
remained unchanged after 12 months, with just mild improvement of other functions.
131
 Further, 10 
only 16% returned to work after the cardiac arrest whereas more than 94% of controls returned to 11 
work.
131
 This study also evaluated quality of life among cardiac arrest survivors and controls; 12 
physical quality of life was not perceived as impaired in either group, however the ‘cases’ 13 
perceived a worse quality of life as a result of memory impairment.
131
 14 
 15 
Therapeutic hypothermia to prevent cognitive impairment after cardiac arrest.  16 
Although the effects of hypothermia have been evaluated in humans and experimental models 17 
before,
141, 142
 in 1956 Marchand and Allan developed an experimental model to measure the 18 
effects of hypothermia on the heart and brain.
143
 The first studies of therapeutic hypothermia in 19 
cardiac arrest patients were performed in the 1950s. Later, Zola-Morgan et al. reported that 20 
ischemic episodes damaged CA1 hippocampal cells.
144
 The benefits of induced hypothermia 21 
were demonstrated in animal models in the nineties.
145
 At the present time, compelling evidence 22 
supports the use of targeted therapeutic hypothermia. Effectiveness of therapeutic hypothermia to 23 
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prevent cognitive impairment has been reported with varying results among different authors.
146
 1 
For example, Fugate et al. followed 56 survivors of cardiac arrest treated with therapeutic 2 
hypothermia. Twenty-month follow-up interviews yielded results favouring the use of this 3 
therapy: 33 patients (60%) were reported as being ‘cognitively normal’, with 79% of working 4 
patients returning to their normal activities after the event.
146
 In contrast, a randomized clinical 5 
trial (RCT) of 70 patients comparing therapeutic hypothermia to a normothermic control group 6 
(without further intervention), found no statistically significant difference in cognitive function 7 
between the two groups, although the authors suggests that differences in the neuropsychological 8 
tests employed (previous prospective studies focussing on memory functions rather than 9 
executive functions) might explain the neutral findings in this RCT.
147
 Current guidelines for 10 
hospital care after cardiac arrest recommend the use of targeted therapeutic hypothermia between 11 
32 and 34°C for 48 hours.
148
 After publication of these guidelines, a systematic review by 12 
Schenone et al. reported that mortality was halved [OR = 0.51, 95% CI (0.4, 0.64)] and 13 
neurological impairment caused by arrest-induced hypoxia was significantly lower [good 14 
neurological outcome OR = 2.48, 95% CI (1.91, 3.22)] in patients who underwent therapeutic 15 
hypothermia compared to those who did not.
149
 16 
In summary, minimising and treating the complications originating from a cardiac arrest 17 
are almost as important as treating the arrest itself. Physicians should perform appropriate 18 
follow-up and referral to a specialized centre that can offer appropriate postcardiac arrest care in 19 
order to minimise the extent of brain damage and to avoid adverse outcomes, since the ultimate 20 
success of medical therapy is not only survival, but preservation of quality of life. 21 
 22 
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6.3 Cardiac implantable electronic devices and cognitive dysfunction 1 
Patients requiring cardiac implantable electronic devices (CIED) are generally older and as such 2 
may have associated cognitive dysfunction. It has also been shown that patients with severe 3 
bradycardia or high-grade AV block may show impaired cognitive function.
150-152
 4 
Bradycardia is also more common in patients treated for dementia with cholinesterase 5 
inhibitor drugs (adjusted hazard ratio (HR) 1.4, 95% CI 1.1-1.6) and increases the risk of 6 
syncope, CIED need, and falls.
153
 A retrospective study showed that patients with cognitive 7 
dysfunction were more likely than those without cognitive deficits to be implanted with a 8 
pacemaker, even after adjusting for clinical risk factors.
154
 Treatment of both permanent or 9 
transient bradycardia with CIEDs has been shown to improve cognition in a number of small 10 
trials.
151, 152, 155
 11 
Although it may be inferred that patients with cognitive impairment and standard device 12 
indications may be at increased risk for device complications, this was not demonstrated in a 13 
study by Jama et al.
156
 However, the survival was lower than in matched controls suggesting that 14 
these patients may have more comorbidities. A small study suggested that the increase in 15 
cerebral blood flow after pacemaker implantation for symptomatic bradycardia resulted in 16 
improvement in cognitive function.
152
 Another small study showed that the improvement was, 17 
however, not significant over a 6-12 months follow-up after pacemaker implantation.
151
 18 
Ventricular pacing may result in impaired hemodynamics and has been associated with AF, 19 
which itself has been associated with multi-infarct dementia. Ventricular pacing was noted to 20 
show a trend towards a detrimental effect on the visual memory score.
157
 It is well known that 21 
CIED may have psychological side effects; this is particularly true for ICD and especially shock 22 
therapy.
159, 160
 Apart from this psychological effect, there may be a direct effect on cognitive 23 
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function. ICD implantation with defibrillation testing has been reported to initially result in 1 
cognitive dysfunction in 31-39% of patients, as determined by neuropsychological testing before 2 
and after ICD implantation in 52 patients, however most patients improve within a year.
161
 3 
Another study in 115 ICD patients observed that cognitive function in memory was poor at 4 
baseline and decreased over 12 months post ICD implantation.
162
 In a small Polish study of 51 5 
patients with primary prevention ICDs, 7 patients who received ICD shocks for ventricular 6 
fibrillation scored worse in neuropsychological measurements compared to patients without such 7 
shocks, suggesting greater cognitive impairment,
163
 which could be multifactorial. However, 8 
further studies are needed to demonstrate whether shock or VF prevention will prevent decline in 9 
cognitive function. 10 
 In contrast, there are several reports that cardiac resynchronization therapy may be 11 
associated with neurocognitive functional improvement.
164-168
 An early systematic review of 3 12 
studies reported improvements in executive functioning and attention. 13 
 14 
6.4 Catheter Ablation 15 
With mounting evidence to suggest an association between arrhythmias and cognitive decline 16 
and dementia, treatment of these arrhythmias has been considered as an option to lower risk of 17 
cognitive decline. As antiarrhythmic drug therapies have variable efficacy and are associated 18 
with many side effects, and medications can directly influence quality of life, mood, and 19 
function
170
, catheter ablation is often employed as a durable non-pharmacological option. 20 
The majority of evidence that catheter ablation may impact cognition is derived from 21 
observational studies of AF management.  Outcomes in a consecutive series of 4,212 patients 22 
who underwent AF ablation were compared (1:4) to 16,848 age/gender matched controls with 23 
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AF (no ablation) and 16,848 age/gender matched controls without AF. In this analysis, stroke 1 
outcomes of patients with AF, and an ablation, were better than patients with AF and no ablation, 2 
but similar to patients without AF
171
. Similarly, long-term outcomes of cognition were better in 3 
AF ablation patients compared to AF patients who did not undergo ablation, including lower 4 
rates of Alzheimer's, senile, and vascular dementia. Cognitive outcomes between those patients 5 
that received an ablation were similar to patients without a history of AF, including all subtypes 6 
of dementia. In patients with atrial flutter stroke rates post ablation are significantly lower 7 
compared to AF patients treated with ablation
172
. However, as these were not RCTs, better 8 
outcomes could have been related to selection bias rather than impact of ablation. 9 
Dementia has not been a traditional endpoint in observational studies of outcomes after 10 
AF ablation. However, stroke and transient ischemic attack (TIA) are commonly reported 11 
endpoints. Long-term cognitive deficits are common after stroke with up to 10% of patients 12 
developing dementia after their first stroke with an incidence that increases to 30-40% with 13 
recurrent stroke.
173
 In a propensity-matched study of 969 consecutive AF ablation patients with a 14 
CHA2DS2-VASc score ≥2, AF ablation was associated with a long-term reduced risk of stroke 15 
[HR: 0.62 (95% CI 0.47-0.82)] and TIA [HR: 0.47 (95% CI 0.20-0.78)].
174
 In a separate 16 
observational study, AF ablation was associated with lower rates of stroke/TIA compared to AF 17 
patients not treated with ablation across all age and CHADS2 strata including patients considered 18 
at high risk for stroke and patients with prior stroke.
175
 In this study, stroke rates in all groups 19 
increased with higher CHADS2 scores, including non-AF patients, consistent with the influence 20 
of systemic risk factors on stroke risk beyond that of AF. 21 
Catheter ablation of all arrhythmias has peri-procedural risks that may have long-term 22 
significant consequences with regard to cognition and dementia risk.  Procedural risk with all 23 
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cardiac left sided procedures may impact long-term cognition due to the presence of peri-1 
procedural thrombus, atheroemboli, cerebral hypoperfusion, sheath and wire manipulation and 2 
management, and anaesthesia.  In patients that undergo right sided cardiac procedures the risk is 3 
anticipated to be lower although paradoxical thromboembolism can occur in the presence of a 4 
septal defect
172
. The risk of stroke during left atrial catheter ablation is estimated at 5 
approximately 0.5-1%.
122
 However asymptomatic or subclinical ischemic lesions develop in up 6 
to 41% of AF ablation patients with an incidence that varies with anticoagulation approach, 7 
ablation tool used, and cranial scan protocol.
122, 123, 176, 177
 In addition, when peri-procedural 8 
transcranial Doppler analysis is used during AF ablation to monitor for emboli, sheath 9 
manipulation, removal and insertion of tools, and using of multiple tools within the left atrium 10 
are significantly associated with microembolic events.
178
 The risk of these lesions is higher (up 11 
to 63%) during ventricular arrhythmia ablation with retro-aortic access and long sheaths in the 12 
aorta being unique risk factors.
179
 13 
To put these incidences in context with other cardiovascular procedures, the estimated 14 
incidence of new brain lesions has been reported to be 8-18% after AF ablation, 11-17% after 15 
coronary angiography or percutaneous coronary intervention, 16-51% after coronary artery 16 
bypass graft, 38-47% after surgical aortic valve replacement, 68-91% after transaortic valve 17 
implantation, 4-34% after carotid endarterectomy, 15-67% after carotid artery stenting, 11-20% 18 
after cerebral angiography, and 10-64% after endovascular aneurysm procedures.
180
  19 
The long-term consequences of asymptomatic or subclinical cerebral ischemic events are 20 
unknown. It stands to reason that cranial injury of any type, if persistent or accumulative can 21 
impact function. However, cognition is not often tested serially after ablation and the 22 
mechanisms that underlie the genesis of these cranial lesions are not fully understood. In the 23 
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prospective Mesh Ablator versus Cryoballoon Pulmonary Vein Ablation of Symptomatic 1 
Paroxysmal Atrial Fibrillation (MACPAF) study, high-resolution diffusion-weighted MRI 2 
imaging, performed within 48 hours after ablation, showed that new brain lesions (range: 1-17) 3 
were present in 43.2% of patients.
123
 Follow-up MRI at 6 months found that 12.5% of the acute 4 
brain lesions after ablation formed a persistent scar. Neuropsychological assessment at 6 months 5 
found that there was not a significant consequence of these lesions on attention or executive 6 
functions, short-term memory, or learning.
123
 However, other studies such as the ERACE study 7 
reported much lower rates of permanent scar indicating the uncertainty in this area.
181
 8 
Based on the limited available data, post AF ablation cognitive dysfunction seems to be 9 
common. In a study of 150 patients who underwent ablation, cognitive dysfunction was evident 10 
in 28% with paroxysmal AF, 27% with persistent AF, and 13% with supraventricular tachycardia 11 
and 0% in control patients with AF who did not undergo ablation. Although these incidences 12 
decreased to 13%, 20%, and 3% at 90 days, measurable cognitive dysfunction persisted; access 13 
time in the left atrium was the most significant procedural variable of risk.
124
 Unfortunately in 14 
this study, MRI imaging was not performed to determine and correlate this dysfunction with 15 
peri-procedural cranial lesions. Neuropsychological outcomes were sought at 3 months in a small 16 
study of 23 patients who underwent ablation with post-procedure diffusion weighted MRI cranial 17 
imaging. New cranial lesions were detected in 3 patients (14%) and one patient suffered a 18 
clinical stroke.
163
 Residual cognitive defects were noted at 3 months with neuropsychological 19 
testing, in particular, in verbal memory (one of five cognitive domains); deterioration was 20 
observed in 56.5% of ablation patients compared to 17.4% of controls.
182
 21 
 22 
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6.5 Implications for EP Procedures and cognitive function 1 
As described in the preceding sections, emerging evidence suggests that various EP procedures 2 
may be associated with cerebral injury and the potential of cognitive decline therefore, it is 3 
timely to consider current evidence and guidelines to minimise these risks. 4 
Over recent years considerable research has focused on how to minimise these procedural 5 
risks during left sided catheter ablation and in particular AF ablation. The routine use of 6 
transesophageal echocardiography (TEE) to identify pre-existing thrombus at the time of AF 7 
ablation remains controversial particularly in an era where most EP procedures will be 8 
performed on uninterrupted anti-coagulation. However, TEE studies have demonstrated that up 9 
to 2% of anticoagulated AF patients may have left atrial appendage thrombus or sludge with risk 10 
varying according to CHA2DS2-VASc score. In the most recent AF ablation 11 
HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement guidelines, 51% of the 12 
writing group members perform a TEE in all patients presenting for AF ablation regardless of 13 
presenting rhythm and anticoagulation status; 71% perform a TEE in patients presenting in AF 14 
even on therapeutic anticoagulation, and 78% perform a TEE in patients not previously 15 
anticoagulated even in sinus rhythm. Computed tomography and intra-cardiac echocardiography 16 
have both also been used to screen for thrombus but evidence from large comparative studies is 17 
lacking. 18 
Evidence suggests that patients with an anticoagulation window period or those requiring 19 
bridging are at increased risk of peri-procedural events. Uninterrupted anticoagulation ensures 20 
the full anticoagulant effect in the early post-procedural phase when embolic events are most 21 
likely to occur.
183, 184
 In this context, in recent years it had become routine to perform AF 22 
ablation on uninterrupted warfarin with a therapeutic INR. Until recently there were little data to 23 
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support this practice for NOACs however, emerging data from both meta-analyses and a recent 1 
large randomized study support the safety of this approach.
183
 This practice is likely to gain 2 
increasing acceptance particularly as reversal agents become more widely available for all 3 
NOACs. 4 
Intra-procedurally, a strategy of more aggressive heparin dosing has evolved over the 5 
past decade in the light of data that patients who have an Activated Clotting TIme (ACT) of 6 
<300 s during the procedure have an increased risk of silent cerebral infarction. The current 7 
consensus document recommends an ACT target of 300-400 with repeated checks at 15-20 8 
minute intervals. In addition, echocardiographic data have demonstrated that thrombus may form 9 
on sheaths immediately following trans-septal puncture; as such 77% of Consensus Document 10 
Writing Group
185
 members give heparin prior to the trans-septal puncture. 11 
Less data exist for ablation of ventricular arrhythmias although a recent study 12 
demonstrated the presence of new silent cerebral infarction in 7/12 patients having ablation of 13 
ventricular tachycardia originating from the left ventricle. The majority of these patients 14 
underwent ablation via a retrograde trans-aortic approach and the target ACT was 300-400 15 
seconds. Whether the incidence would be lower using a trans-septal approach is unknown. 16 
Similarly, limited data exist regarding the impact of device implantation on cognitive 17 
function and these have been discussed in Section 6.2. Until more comprehensive data are 18 
available it seems prudent to follow recommendations in the 2015 19 
HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable 20 
cardioverter-defibrillator programming and testing even though data that such an approach 21 
minimises cognitive impact are lacking. These include the 2A recommendation that: “It is 22 
reasonable to omit defibrillation efficacy testing in patients undergoing initial left pectoral 23 
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transvenous ICD implantation procedures where appropriate sensing, pacing, and impedance 1 
values are obtained with fluoroscopically well-positioned right ventricular leads”; and the Class 2 
3 recommendation that “Defibrillation efficacy testing at the time of implantation of a 3 
transvenous ICD should not be performed on patients with a documented nonchronic cardiac 4 
thrombus, AF or atrial flutter without adequate systemic anticoagulation, critical aortic stenosis, 5 
unstable coronary artery disease, recent stroke or TIA, hemodynamic instability, or other known 6 
morbidities associated with poor outcomes”. 7 
Regarding the impact of left atrial appendage occlusion (LAAO) procedures on cognitive 8 
function, MRI-detected new acute brain lesions were detected in 12 of 23 patients (52%) after 9 
LAAO procedures using the Amulet, Occlutech or LAmbre devices. New brain lesions were 10 
associated with a higher number of left atrial appendage angiographies although there was no 11 
apparent impact on cognitive testing.
186
 Procedural stroke, typically related to air embolism, has 12 
also been reported with the Watchman device in the PROTECT trial, although impact on long 13 
term cognition is unknown.
187, 188
 However, any long term impact on cognition has not been 14 
reported.   15 
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7. Current knowledge gaps, future directions and areas for research  1 
Global management of dementia syndromes has been recently set as a public health priority, and 2 
the World Health Organization has prioritized seven research domains to reduce the global 3 
burden of dementia
189
: 1) Prevention, identification, and reduction of risk; 2) Quality of care for 4 
people with dementia and their carers; 3) Delivery of care and services for people with dementia 5 
and their carers; 4) Diagnosis, biomarker development, and disease monitoring; 5) 6 
Pharmacological and non-pharmacological clinical–translational research; 6) Public awareness 7 
and understanding, and 7) Physiology and progression of normal ageing and disease 8 
pathogenesis. Other expert groups have also provided recommendations for further progress and 9 
improvements in dementia-related research
190
 and highlighted knowledge gaps in cardiovascular 10 
care of the elderly, including those with cognitive impairment
191
. Declining incidence and age-11 
specific prevalence of dementia in high-income countries
192-195
 implies that dementia risk is 12 
modifiable, likely through improved management of cardiovascular risk factors
196
 and 13 
psychosocial factors
190, 197-199
. Although dementia-prevention RCTs failed to confirm many 14 
signals from observational studies, those RCTs highlighted some key methodological issues to 15 
be considered in contemporary trials (Table 9). 16 
Elderly patients with cognitive impairment commonly have mixed pathologies, including 17 
cardiovascular disease (e.g., AF and heart failure)
81, 86, 200-202
 but the complexity of shared 18 
pathological pathways and risk factors is still poorly understood and warrants further research. 19 
Better understanding of the mechanisms and determinants of AF-related cognitive 20 
impairment/dementia beyond aging and stroke would inform AF-specific preventive strategies to 21 
attenuate and/or postpone cognitive deterioration. Prospective studies addressing the long-term 22 
effects of AF treatments directed towards rhythm control, reduction of total AF burden and 23 
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improvement in cardiac function (i.e., catheter ablation and pharmacotherapy) on cognitive 1 
function are needed. Inherent to achieving these targets is consistent utilization of well-validated 2 
neurocognitive measures. Also, the effects of lifestyle changes resulting in weight loss, 3 
improvement in overall cardio-metabolic risk profile and reduced AF burden need to be 4 
investigated. Further research is needed to optimise rate control in AF relative to cognitive 5 
function.  6 
Cognitive endpoints were not addressed in the recent large RCTs of OAC (VKA or 7 
NOACs) for thromboprophylaxis in AF, with one exception, the  Birmingham Atrial Fibrillation 8 
Treatment of the Aged Study (BAFTA) which reported better cognitive function in elderly 9 
patients receiving warfarin compared to aspirin
114
. In retrospective observational studies the risk 10 
of dementia increased with poor management of VKA (a low TTR)
76, 113
, whilst NOAC use was 11 
associated with lower risk for dementia compared to warfarin
115
. Observational data on AF 12 
patients diagnosed with dementia consistently shows significant VKA underuse or 13 
discontinuation
62
 even post-stroke
203
, despite similar VKA-related bleeding risk irrespective of 14 
the cognitive status. Large prospective studies with pre-specified cognitive outcomes are needed 15 
to identify optimal thrombo-prophylactic strategies for AF patients with cognitive 16 
impairment/dementia. Importantly, the effects of early AF treatment or primary AF prevention 17 
on cognitive deterioration in patients at risk for both conditions remain to be elucidated. 18 
Elderly patients and those with cognitive impairment/dementia were generally under-19 
represented in catheter ablation and CIED (i.e., ICD and CRT) trials. Studies are needed to better 20 
define the risks and benefits of cardiac arrhythmias ablation or CIED implantation, long-term 21 
effects of these interventions on cognitive status and optimal strategies for shared decision-22 
making and end-of-life decisions in these patients (Table 9).  23 
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Table 9. Knowledge gaps and areas for further research. 1 
General dementia-related 
research domains* 
Knowledge gap(s) Further research 
Distinguishing progression 
of normal aging from pre-
clinical cognitive decline 
Physiology of normal 
aging /pathological 
neurodegenerative 
processes. 
 Large international population-based longitudinal studies of aging and 
dementia 
 Contribution of vascular conditions, inflammation, oxidative stress, and the 
immune system to neurodegenerative processes causing dementia 
Identification of the risk 
factors and risk reduction 
Interactions of shared 
pathological pathways 
and risk factors. 
 Interactions of modifiable and non-modifiable dementia risk factors in 
population-based studies  
 Feasibility, administration and effectiveness of interventions addressing 
dementia risk factors 
Early diagnosis, 
biomarkers and disease 
monitoring 
Effective strategies for 
cognitive surveillance; 
Early detection of 
cognitive impairment; 
Monitoring of disease 
progression.   
 Interventions for timely and accurate diagnosis of cognitive impairment or 
dementia at the primary health-care level. Better characterization of 
different dementia types 
 Strategies for longitudinal surveillance of healthy individuals to distinguish 
(and timely diagnose) pre-clinical neurodegenerative diseases with 
cognitive impairment versus normal aging 
 Validation and standardization of available cerebrospinal fluid and brain 
imaging biomarkers of dementia for research and clinical use  
 Development and validation of novel biological, genetic, behavioural or 
cognitive biomarkers with predictive value at pre-dementia stages 
Prevention of cognitive 
impairment/dementia 
Effective preventive 
strategies in general 
population. 
 Exploring single- and multi-domain approaches for primary and secondary 
prevention of dementia based on evidence on risk / protective factors and 
the relationship with other chronic diseases  
 Prevention studies need to start in mid-life and have a long follow-up to 
identify “windows of opportunity” for effective interventions 
Pharmacological and non- Effective dementia-  Identification, validation and implementation of better defined outcome 
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pharmacological clinical-
translational research on 
dementia diagnosis and 
treatment 
specific therapies are not 
available yet. 
measures for clinical trials of cognition, function and other biomarkers of 
neurodegenerative diseases causing dementia 
 Improvement in differentiation of dementia types 
 Improvement in the selection of patients eligible for clinical trials of 
cognitive impairment or dementia 
 Investigation of combination therapies for dementia and diversification of 
investigational therapeutic approaches (pharmacological and non-
pharmacological interventions)  
AF-specific research 
domains  
Knowledge gap(s) Further research 
Association of AF with 
cognitive impairment or 
dementia 
Underlying mechanisms 
beyond clinically overt 
strokes, silent strokes 
and aging are poorly 
understood. 
 Significance and contribution of cerebral hypoperfusion due to irregular 
heart rhythm and impaired cardiac function in AF patients, AF-associated 
hypercoagulability and OAC-related cerebral micro-bleeds to cognitive 
deterioration and development of dementia 
 Association of AF burden (i.e., paroxysmal versus non-paroxysmal AF) 
with cognitive status 
 Potential role of atrial cardiomyopathy in the development of cognitive 
impairment/dementia  
Time-course of cognitive 
impairment in AF patients 
Mechanism(s) of 
accelerated development 
of dementia in AF 
patients. 
 Large prospective population-based studies on AF and non-AF patients to 
identify the time-course of cognitive deterioration by AF status and risk 
factors for accelerated dementia, thus providing a roadmap for prevention 
strategies 
 Identification and validation of clinical predictors and biomarkers to 
identify AF patients at increased risk of cognitive impairment/dementia 
Rhythm control and other 
strategies, including 
ablation, for AF burden 
Short- and long-term 
effects on cognitive 
function in AF patients 
 Better representation of elderly and other AF patients with, or at risk for 
cognitive impairment or dementia in future rhythm control and AF ablation 
studies 
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reduction 
 
 Prospective investigation of the effects of rhythm control, AF ablation and 
other strategies for AF burden reduction on cognitive function and 
prevention, attenuation or delay of cognitive impairment/dementia 
 Prospective investigation of the effects of different ablation energy sources 
(e.g., radiofrequency, cryoablation) on cognitive function 
Pharmacological rate 
control therapies in AF;  
AV node ablation with 
permanent pacemaker 
implantation for rate 
control in AF 
Short- and long-term 
effects on cognitive 
function in AF patients 
 Prospective investigation of the effects of strict versus lenient rate control 
on cognitive function in AF patients including those with cognitive 
impairment or dementia  
 Better representation of elderly and other AF patients with, or at risk for 
cognitive impairment or dementia in future prospective studies investigating 
the effects of AV node ablation with permanent pacemaker implantation on 
cognitive function and prevention, attenuation or delay of cognitive 
impairment or dementia 
VKA, NOACs and non-
pharmacological (LAAO) 
thromboprophylaxis in AF 
Long-term effects on 
cognitive function in AF 
patients 
 Prospective studies of VKA, NOACs and LAAO long-term effects on 
cognitive function in AF patients with baseline normal cognitive status, 
cognitive impairment or dementia 
 Assessment of benefits of VKA, NOACs for reduction of cognitive decline 
among patients with micro-haemorrhages  
 Identification and validation of clinical/biomarker predictors of cognitive 
impairment/dementia in anticoagulated AF patients or those with LAAO 
 Studies on the consequences of non-adherence or permanent OAC 
discontinuation in AF patients with cognitive impairment or dementia 
Screening for 
asymptomatic AF 
Asymptomatic AF-
associated risk of 
cognitive impairment 
 Assessment of cognitive impairment and dementia in patients with 
asymptomatic AF 
 Assessment of the effect of asymptomatic AF treatment on prevention, 
attenuation or delay of cognitive impairment or dementia 
Early AF detection and Effects of early  Studies with pre-specified primary endpoint of cognitive function 
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treatment  aggressive rhythm 
control on cognitive 
function 
 Inclusion of elderly and other AF patients with, or at risk for cognitive 
impairment or dementia 
Primary prevention of AF Effective interventions 
for primary prevention 
(ongoing research) 
 Effects of dietary intervention, improved blood pressure control and other 
risk factors control on cognitive function in patients at risk of AF and 
cognitive impairment/dementia, and in non-AF patients with cognitive 
impairment/dementia 
Other arrhythmia-
specific research domains  
Knowledge gap(s) Further research 
SCD risk assessment and 
SCD prevention 
Effective strategies in 
individuals with 
cognitive limitations 
 Improvement of non-invasive risk assessment and identification of 
screening tools applicable to older and other patients with, or at risk for 
cognitive impairment or dementia 
 SCD prevention studies to include cognitive function endpoints 
Catheter ablation of 
ventricular arrhythmias 
Short and long-term 
effects in individuals 
with cognitive 
limitations 
 Better understanding of the role of catheter ablation of ventricular 
arrhythmias in older and other patients with, or at risk for cognitive 
impairment/dementia, including studies of competing risk of death caused 
by ventricular arrhythmias versus other causes 
 Further studies on the impact of left sided and trans-septal vs trans-aortic 
access on cognitive function   
ICD for primary and 
secondary prevention 
Short- and long-term 
effects in patients with 
cognitive limitations 
 Studies on ICD implantation outcomes including procedural complications, 
QALY gain, healthcare costs and competing risk of death in patients with 
cognitive impairment or dementia 
 Studies estimating life extension with ICD and end-of-life issues in patients 
with cognitive impairment or dementia  
 Further research on impact of antitachycardia pacing vs. defibrillation on 
cognitive function 
CRT Effects in patients with  Studies of the impact of CRT, with or without ICD, on QoL and cognitive 
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cognitive limitations function in patients with, or at risk for cognitive impairment or dementia  
*Compiled and modified from the References 132-134 
189-191
 (for details on the quality of care, delivery of care and 1 
services for individuals with dementia and public awareness and understanding see the cited documents). AF: Atrial 2 
fibrillation; AV: atrioventricular; CRT: Cardiac resynchronization therapy; ICD: Implantable cardioverter 3 
defibrillator; LAAO: Left atrial appendage occlusion; NOAC: Non-VKA oral anticoagulant; QALY: Quality-4 
adjusted life-years; QoL: Quality of life; SCD: Sudden cardiac death; VKA: Vitamin K antagonist.   5 
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8. Recommendations 1 
Interventions that can be considered for prevention of cognitive dysfunction in atrial fibrillation 2 
patients are summarized in Table 10. The writing committee reached consensus on 3 
recommendations summarized in Table 11. 4 
Table 10.  Interventions to be considered for prevention of cognitive dysfunction in atrial 5 
fibrillation patients  6 
Pharmacological interventions 
 In relation to AF management: 
- Oral anticoagulation (early identification of appropriate candidates, improving 
drug adherence, avoiding warfarin in those with poor TTR, optimal TTR 
management) 
- Rhythm control 
- Antihypertensive treatment 
- Treatment of concomitant heart failure 
 Non-specific pharmacological interventions: 
- Glycaemic control 
- Hormone replacement therapy 
- Avoid aspirin therapy unless specific clinical indication present 
 Alzheimer’s disease-specific pharmacological interventions 
Multifactorial vascular risk factor management  
 Targeting blood pressure, cholesterol, diabetes, sleep apnoea, and obesity 
via diet, medication, smoking cessation, and physical activity 
Nutritional interventions 
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 Low levels of vitamin D and B12, and folate increase risk, but the value of 
supplementation remains unproven.  Calcium supplementation in women has 
been associated with increased dementia risk.
204-206
  The value of modulating 
cognitive function based on educational interventions is uncertain. 
 Weight loss in obesity207 
Others 
 Cognitive activities or training  
 Physical exercise 
 Multi-domain interventions 
  1 
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Table 11: Recommendations for measures to prevent cognitive dysfunction in AF patients. 1 
Preventive Measures of Cognitive Dysfunction in Patients 
with Atrial Fibrillation  
Class Ref 
Appropriate anticoagulation in patients with AF and stroke 
risk factors should be applied for the prevention of cognitive 
dysfunction.   
108, 112  
Consider NOAC instead of VKA when using oral 
anticoagulation for the prevention of stroke in AF, which may 
have a beneficial effect on subsequent cognitive disorders  
108, 115
 
In patients with AF managed with long term VKA, a high 
anticoagulation time in therapeutic range may be beneficial for 
optimal prevention of new-onset dementia  
76, 108
 
General health measures (prevention of smoking, 
hypertension, obesity and diabetes, sleep apnoea, and 
appropriate control of all risk factors) may reduce the 
concomitant risks of AF (new onset or recurrences) and 
stroke, with a putative benefit on cognitive function. 
 
108, 116
 
Prevention of cognitive dysfunction in AF may include 
general measures proposed in vascular dementia or 
Alzheimer’s disease.   
117
 
Cognitive assessment should be performed in AF patients 
where there is suspicion of cognitive impairment. 
 
208
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AF: atrial fibrillation; NOAC: non-vitamin-K antagonist oral anticoagulant; VKA: vitamin-K-1 
antagonist  2 
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Figure Legends 1 
 2 
Figure 1. 3 
Different mechanisms through which atrial fibrillation may contribute to cognitive impairment. 4 
Potential interventions are shown in red. 5 
CO: cardiac output; CRP: C-reactive protein; DM: diabetes mellitus; HF: heart failure; HTN: 6 
hypertension; IL: Interleukin; OSA: obstructive sleep apnoea 7 
*Some of the reported brain morphometric changes include: hippocampus atrophy, white matter 8 
hyperintensities, and frontal medial lobe atrophy. Reproduced with permission.
64
 9 
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Figure 1. Potential mechanisms for the association between atrial fibrillation and cognitive impairment. 1 
 2 
 3 
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